Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | DRD2 | P14416 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 11/20 | 0.73 |
| ▸ | HTR2C | P28335 | 10/20 | 0.73 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.63 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274149 | 0.88 | HTR7 (1.00) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL30274365 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL3713285 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL6088731 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL23875880 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL23875899 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL30274410 | 0.86 | HTR7 (0.83) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL3709723 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL6786360 | 0.86 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19DRD2 | |
| SCHEMBL3568230 | 0.85 | HTR7 (1.00) | HTR7CYP3A4CYP2D6CYP2C19DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987115-B2 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-17 | — | — | US | disclosed |
| EP-1347759-B1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1347759-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040053954-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1347759-A1 | ANTIBACTERIAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002062339-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053954-A1 | Antibacterial compounds | RER1, REL, RRS1 | HTR7 1866/4885CYP3A4 1994/4885CYP2D6 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.